K. Skorey

发表

Development of a robust scintillation proximity assay for protein tyrosine phosphatase 1B using the catalytically inactive (C215S) mutant.

B. Kennedy, C. Ramachandran, K. Skorey, 2001, Analytical biochemistry.

Broadening the Spectrum of β-Lactam Antibiotics through Inhibition of Signal Peptidase Type I

J. Phillips, A. Therien, P. Beaulieu, 2012, Antimicrobial Agents and Chemotherapy.

The YRD Motif Is a Major Determinant of Substrate and Inhibitor Specificity in T-cell Protein-tyrosine Phosphatase*

C. Bayly, C. Desponts, E. Asante-Appiah, 2001, The Journal of Biological Chemistry.

How Does Alendronate Inhibit Protein-tyrosine Phosphatases?*

M. Gresser, C. Ramachandran, Qingping Wang, 1997, The Journal of Biological Chemistry.

Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes.

D. Waddleton, K. Skorey, T. Leriche, 2006, Analytical biochemistry.

The development of potent non-peptidic PTP-1B inhibitors.

E. Asante-Appiah, Y. Boie, B. Kennedy, 2004, Bioorganic & medicinal chemistry letters.

Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells

D. Riendeau, B. Kennedy, S. Charleson, 1997, Inflammation Research.

Using mass spectrometry to study the photo-affinity labeling of protein tyrosine phosphatase 1B

K. Skorey, K. Bateman, D. McKay, 2004 .

Direct O-acylation of small molecules containing CO2----HN .rarw. HO units by a distorted amide: enhancement of amine basicity by a pendant carboxylate in a serine protease mimic

K. Skorey, R. S. Brown, V. Somayaji, 1989 .

Simplified assays of lipolysis enzymes for drug discovery and specificity assessment of known inhibitors

M. Prentki, K. Skorey, J. Iglesias, 2016, Journal of Lipid Research.

Simplified assays of lipolysis enzymes for drug discovery and specificity assessment of of known inhibitors Running title : Lipases and specificity of inhibitors

K. Skorey, J. Iglesias, S. Madiraju, 2015 .

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.

J. Falgueyret, R. Oballa, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

High-Throughput Scintillation Proximity Assay for Stearoyl-CoA Desaturase-1

J. Falgueyret, P. Tawa, Sébastien Guiral, 2011, Journal of biomolecular screening.

2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.

J. Falgueyret, R. Oballa, P. Tawa, 2010, Bioorganic & medicinal chemistry letters.

From indomethacin to a selective COX-2 inhibitor. Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors.

P. Prasit, C. Chan, S. Charleson, 1997, Advances in experimental medicine and biology.

From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

C. Bayly, D. Denis, P. Prasit, 1996 .

Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors.

C. Bayly, E. Asante-Appiah, Y. Boie, 2004, Bioorganic & medicinal chemistry letters.

Broadening the Spectrum of (cid:1) -Lactam Antibiotics through Inhibition of Signal Peptidase Type I

J. Phillips, A. Therien, P. Beaulieu, 2012 .

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.

Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence, and ultraviolet-visible spectroscopy: redox cycling between ferrous and ferric states.

J. K. Grady, M. Percival, D. Riendeau, 1993, Biochemistry.

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

David A. Powell, Lei Zhang, R. Oballa, 2011, Journal of medicinal chemistry.

Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics

Eric Langlois, Alexandre Caron, Mihai Petcu, 2012, Science Translational Medicine.

SYNTHESIS AND BIOLOGICAL EVALUATION OF BOTH ENANTIOMERS OF L-761,000 AS INHIBITORS OF CYCLOOXYGENASE 1 AND 2

Yves Leblanc, Daniel Guay, Petpiboon Prasit, 1996 .

Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.

Claude Dufresne, Yves Leblanc, Michel Therien, 2008, Bioorganic & medicinal chemistry letters.

Protein tyrosine phosphatase: enzymatic assays.

B. Kennedy, K. Skorey, J. Montalibet, 2005, Methods.

The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.

C. Bayly, C. Desponts, E. Asante-Appiah, 2003, Biochemistry.

Synthesis of a novel peptidic photoaffinity probe for the PTP-1B enzyme.

R. Zamboni, D. Waddleton, C. Ramachandran, 2004, Bioorganic & medicinal chemistry letters.

Residues Distant from the Active Site Influence Protein-tyrosine Phosphatase 1B Inhibitor Binding*

E. Asante-Appiah, B. Kennedy, G. Scapin, 2006, Journal of Biological Chemistry.

Discovery of Novel P2Y14 Agonist and Antagonist Using Conventional and Nonconventional Methods

C. Bayly, A. Therien, C. Brideau, 2011, Journal of biomolecular screening.

Peptidase Type I Antibiotics through Inhibition of Signal-Lactam β Broadening the Spectrum of

Alexandre Caron, Mihai Petcu, Kenneth E. Wilson, 2012 .

A two-component affinity chromatography purification of Helix pomatia arylsulfatase by tyrosine vanadate.

M. Gresser, K. Skorey, G. Huyer, 1999, Protein expression and purification.

Molecular structure of 3,4,5-trihydro-2-oxo-1,5-ethanobenzazepine and its reaction with .beta.-amino alcohols as a model for the acylation step of the serine proteases

K. Skorey, R. S. Brown, R. Ball, 1986 .

Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.